evotecan
hospira produtos hospitalares ltda - antineoplasico
evotecan
wyeth indÚstria farmacÊutica ltda - antineoplasico
leflunomida
germed farmaceutica ltda - antinflamatorios antireumaticos
leflunomida
legrand pharma indÚstria farmacÊutica ltda - antinflamatorios antireumaticos
lemida
ems sigma pharma ltda - antinflamatorios antireumaticos
toporan
ucb biopharma ltda. - antineoplasico
teriflunomida
natcofarma do brasil ltda - teriflunomida - imunomodulador
arava
sanofi medley farmacÊutica ltda. - leflunomida - antinflamatorios antireumaticos
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agentes antineoplásicos - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.